AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) and Astellas Pharma Inc. Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, May 31 – June 4, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news